Foscarbidopa
As of the edition of 20 October 2026, Foscarbidopa is a small molecule: marketed, first approved in 2022 (JP); acts on DDC; US protection ends in 2035.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Vyalev
- First approved
- 23 December 2022 (JP)
- Approvals on record
- 5 in 5 regions
- Holder of the most recent approval
- AbbVie
US protection
US protection ends in 2035.
The last listed US drug-substance patent ends in 2035. The application that gives this date is held by AbbVie.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product3 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 3 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DDC | Aromatic-L-amino-acid decarboxylase | P20711 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Originator | 2022 to now |